Literature DB >> 7494385

Neither the 5-HT1A- nor the 5-HT2-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on forced-swimming-induced immobility in mice.

T Egawa1, Y Ichimaru, T Imanishi, A Sawa.   

Abstract

The effect of fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor, was studied in the forced-swimming test, a model of depression, in mice. Fluvoxamine at 60 mg/kg, p.o. significantly decreased the immobility time in the forced-swimming test. A similar effect was observed by the selective norepinephrine reuptake inhibitor desipramine at the same dose. Furthermore, the suppression of immobility time was slightly potentiated by repeated administration of fluvoxamine, and a significant effect was observed at 30 mg/kg, p.o. The effect of fluvoxamine on forced-swimming was unaffected by the 5-HT2 antagonist ritanserin. On the other hand, the 5-HT1A antagonist NAN-190 (1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine) potentiated the effect of fluvoxamine on forced-swimming. It is expected, however, that a 5-HT1A antagonist should antagonize the effect of fluvoxamine when 5-HT1A mediates the suppressive effect of fluvoxamine on the immobility time in forced-swimming. From these results, neither the 5-HT1A- nor the 5-HT2-receptor subtype is involved in the suppressive effect of fluvoxamine on the immobility associated with forced-swimming.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494385     DOI: 10.1254/jjp.68.71

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  1 in total

1.  Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization.

Authors:  Keiichiro Hayashi; Hiroyuki Michiue; Hiroshi Yamada; Katsuyoshi Takata; Hiroki Nakayama; Fan-Yan Wei; Atsushi Fujimura; Hiroshi Tazawa; Akira Asai; Naohisa Ogo; Hiroyuki Miyachi; Tei-ichi Nishiki; Kazuhito Tomizawa; Kohji Takei; Hideki Matsui
Journal:  Sci Rep       Date:  2016-03-18       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.